FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968857592> ?p ?o ?g. }

• W1968857592 endingPage "216" @default.
• W1968857592 startingPage "211" @default.
• W1968857592 abstract "Imatinib has so far been the first-choice treatment in chronic myeloid leukemia (CML) with excellent results. However, only a proportion of patients achieve major molecular response. Hence, the need to find whether there are some factors that affect the response to treatment is essential. This study aimed to investigate the allele and genotype frequencies of single nucleotide polymorphisms (SNPs) of SLCO1B3 (T334G) and CYP3A5*3 in CML patients undergoing imatinib treatment and to determine whether SNPs of these two genes could predict the response of imatinib therapy in CML patients.We investigated SLCO1B3 (T334G) and CYP3A5*3 polymorphisms by Polymerase Chain Reaction-restriction fragment length polymorphism in 86 Philadelphia positive newly diagnosed Egyptian CML patients (78 patients in chronic phase and 8 patients in accelerated phase). All patients received imatinib therapy and were followed for at least one and half years. The response to imatinib therapy was evaluated by recording the hematological response, cytogenetic response, and molecular response according to the European Leukemia Net criteria.This study included 86 Philadelphia positive newly diagnosed CML patients, 78 in the early chronic phase and 8 in the accelerated phase. In the chronic phase patients, no association between SLCO1B3 (T334G) exon 3 polymorphism and response to imatinib therapy was detected (P = 0.938) while CYP3A5*3 gene polymorphism was associated with inferior outcome (P < 0.001). In the group of accelerated phase patients, the SLCO1B3 polymorphic variants (TG) and (GG) were detected equally with none of the patients in this group having the homozygous wild form (TT). The homozygous state for the CYP3A5*3 allele was the most frequent (50%) and the homozygous state for the CYP3A5*1 allele was the least frequent (12.5%) in this group.CYP3A5*3 polymorphism was associated with imatinib efficacy while the SNP SLCO1B3 (T334G) was not associated with the response to imatinib treatment in Egyptian patients with CML in chronic phase. These results prompt us to explore the effect of CYP3A5*3 in CML patients taking imatinib in a larger scale study." @default.
• W1968857592 created "2016-06-24" @default.
• W1968857592 creator A5002720680 @default.
• W1968857592 creator A5080659999 @default.
• W1968857592 date "2013-07-01" @default.
• W1968857592 modified "2023-10-16" @default.
• W1968857592 title "Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?" @default.
• W1968857592 cites W1968152930 @default.
• W1968857592 cites W1985346980 @default.
• W1968857592 cites W1990542385 @default.
• W1968857592 cites W2012678957 @default.
• W1968857592 cites W2014933948 @default.
• W1968857592 cites W2032034515 @default.
• W1968857592 cites W2034074778 @default.
• W1968857592 cites W2043707585 @default.
• W1968857592 cites W2048521506 @default.
• W1968857592 cites W2055515709 @default.
• W1968857592 cites W2062203984 @default.
• W1968857592 cites W2073020088 @default.
• W1968857592 cites W2090486200 @default.
• W1968857592 cites W2105902511 @default.
• W1968857592 cites W2113070658 @default.
• W1968857592 cites W2120437980 @default.
• W1968857592 cites W2124575784 @default.
• W1968857592 cites W2125399228 @default.
• W1968857592 cites W2151486690 @default.
• W1968857592 cites W2162340188 @default.
• W1968857592 cites W2166654361 @default.
• W1968857592 cites W43331981 @default.
• W1968857592 doi "https://doi.org/10.1179/1607845412y.0000000067" @default.
• W1968857592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23394475" @default.
• W1968857592 hasPublicationYear "2013" @default.
• W1968857592 type Work @default.
• W1968857592 sameAs 1968857592 @default.
• W1968857592 citedByCount "18" @default.
• W1968857592 countsByYear W19688575922013 @default.
• W1968857592 countsByYear W19688575922014 @default.
• W1968857592 countsByYear W19688575922015 @default.
• W1968857592 countsByYear W19688575922016 @default.
• W1968857592 countsByYear W19688575922018 @default.
• W1968857592 countsByYear W19688575922020 @default.
• W1968857592 countsByYear W19688575922021 @default.
• W1968857592 countsByYear W19688575922022 @default.
• W1968857592 countsByYear W19688575922023 @default.
• W1968857592 crossrefType "journal-article" @default.
• W1968857592 hasAuthorship W1968857592A5002720680 @default.
• W1968857592 hasAuthorship W1968857592A5080659999 @default.
• W1968857592 hasConcept C104317684 @default.
• W1968857592 hasConcept C126322002 @default.
• W1968857592 hasConcept C135763542 @default.
• W1968857592 hasConcept C138626823 @default.
• W1968857592 hasConcept C143998085 @default.
• W1968857592 hasConcept C153209595 @default.
• W1968857592 hasConcept C203014093 @default.
• W1968857592 hasConcept C2777583451 @default.
• W1968857592 hasConcept C2778729363 @default.
• W1968857592 hasConcept C2778904597 @default.
• W1968857592 hasConcept C54355233 @default.
• W1968857592 hasConcept C71924100 @default.
• W1968857592 hasConcept C86803240 @default.
• W1968857592 hasConcept C90924648 @default.
• W1968857592 hasConcept C92137452 @default.
• W1968857592 hasConceptScore W1968857592C104317684 @default.
• W1968857592 hasConceptScore W1968857592C126322002 @default.
• W1968857592 hasConceptScore W1968857592C135763542 @default.
• W1968857592 hasConceptScore W1968857592C138626823 @default.
• W1968857592 hasConceptScore W1968857592C143998085 @default.
• W1968857592 hasConceptScore W1968857592C153209595 @default.
• W1968857592 hasConceptScore W1968857592C203014093 @default.
• W1968857592 hasConceptScore W1968857592C2777583451 @default.
• W1968857592 hasConceptScore W1968857592C2778729363 @default.
• W1968857592 hasConceptScore W1968857592C2778904597 @default.
• W1968857592 hasConceptScore W1968857592C54355233 @default.
• W1968857592 hasConceptScore W1968857592C71924100 @default.
• W1968857592 hasConceptScore W1968857592C86803240 @default.
• W1968857592 hasConceptScore W1968857592C90924648 @default.
• W1968857592 hasConceptScore W1968857592C92137452 @default.
• W1968857592 hasIssue "4" @default.
• W1968857592 hasLocation W19688575921 @default.
• W1968857592 hasLocation W19688575922 @default.
• W1968857592 hasOpenAccess W1968857592 @default.
• W1968857592 hasPrimaryLocation W19688575921 @default.
• W1968857592 hasRelatedWork W16693249 @default.
• W1968857592 hasRelatedWork W1994457998 @default.
• W1968857592 hasRelatedWork W2027474437 @default.
• W1968857592 hasRelatedWork W2061741321 @default.
• W1968857592 hasRelatedWork W2122443624 @default.
• W1968857592 hasRelatedWork W2137016351 @default.
• W1968857592 hasRelatedWork W2156238761 @default.
• W1968857592 hasRelatedWork W2530384526 @default.
• W1968857592 hasRelatedWork W2587915732 @default.
• W1968857592 hasRelatedWork W2979624432 @default.
• W1968857592 hasVolume "18" @default.
• W1968857592 isParatext "false" @default.
• W1968857592 isRetracted "false" @default.
• W1968857592 magId "1968857592" @default.
• W1968857592 workType "article" @default.